On the blog now:
Town Hall - Recent months have been eventful and largely rough for Cyberonics Inc., including news the medical-device company is unlikely to win Medicare reimbursement approval for its depression-treatment system. That follows Duke Balancing Demand Vs. Global
Source: www.townhall.com
Some insurers raise drug prices after enrollment
USA Today - Researchers tracked the changes among plans in five states in five drugs: blood pressure drug Altace; pain-killer Celebrex; cholesterol drug Lipitor; angina drug Nifedipine ER; and depression treatment Zoloft. Costs include co-payments and prices
Source: www.usatoday.com
Stone Age solutions to modern-day depression
Belleville News-Democrat - Depression treatment often centers on talk therapy and antidepressant drugs. The drugs have been lifesavers for many people. But antidepressants aren't working as well as advertised, Ilardi said, and their side effects can go from bad to devastating
Source: www.belleville.com
Stockpickr: How to Win a Stock-Picking Contest
Street.Com - The stock is 33% off of its highs because it remains unclear if its depression-treatment system will have any material effect on patients. That said, if this stock should hear one piece of good news, it will get pushed up past $30. Icahn tends to
Source: www.thestreet.com
Click here for more information about symptom of depression symptom of depression
<< Home